This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.
Research
Latest papers
Conventionvs. Innovation I: Digital technology will replace clinic-based care in Parkinson disease.
Parkinsonism & related disorders · 2024 · senior author
Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia.
Movement disorders clinical practice · 2022
Latest funding
- $1,021,276
Genome targeting by highly accurate design of Zinc Fingers to enable novel therapeutics and research tools
CIHR · 2023 · Co-investigator
- $100,000
Genome targeting by highly accurate design of Zinc Fingers to enable novel therapeutics and research tools
CIHR · 2022 · Co-investigator
- $1,438,200
An integrated strategy to identify inhibitors of protein-protein interactions as potential therapeutics for Parkinson's disease
CIHR · 2018 · Nominated PI
2 publications.
Conventionvs. Innovation I: Digital technology will replace clinic-based care in Parkinson disease.
Schneider RB, Phillips O, Kalia L
Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia.
Sáenz-Farret M, Lang AE, Kalia L, Cunha I, Sousa M, Kuhlman G, Ganos C, Munhoz RP, Fasano A, Piña-Avilés CE, Zúñiga-Ramírez C
Genome targeting by highly accurate design of Zinc Fingers to enable novel therapeutics and research tools
Principal investigators: Kim, Philip M
Keywords: Deep Learning; Epigenetic Editing; Gene Editing; Gene Regulation; Genome Targeting; Machine Learning; Zinc Finger
Genome targeting by highly accurate design of Zinc Fingers to enable novel therapeutics and research tools
Principal investigators: Kim, Philip M
Keywords: Deep Learning; Epigenetic Editing; Gene Editing; Gene Regulation; Genome Targeting; Machine Learning; Zinc Finger
An integrated strategy to identify inhibitors of protein-protein interactions as potential therapeutics for Parkinson's disease
Principal investigators: Kalia, Lorraine V
Keywords: Alpha-Synuclein; High-Throughput Screen; Neurodegeneration; Parkinson'S Disease; Peptide Inhibitors; Pooled Lentiviral Screen; Protein Aggregation; Protein-Protein Interactions; Rat Model; Yeast Model
Molecular mechanisms of neurodegeneration in Parkinson's disease
Principal investigators: Kalia, Lorraine V
Keywords: Alpha-Synuclein; C. Elegans Models; Cell Models; Drug Discovery; Neurodegeneration; Neuropathology; Parkinson'S Disease; Protein Aggregation; Proteostasis; Rodent Models
The role of co-chaperone molecules in proteostasis
Principal investigators: Kalia, Lorraine
Molecular mechanisms of neurodegeneration in Parkinson's disease
Principal investigators: Kalia, Lorraine V
Keywords: Alpha-Synuclein; Animal Models (C. Elegans); Animal Models (Rodent); Cell Culture Models; Drug Screens; Immunohistochemistry; Molecular Biology; Molecular Mechanisms Of Disease; Protein Biochemistry; Proteostasis
Identifying regulators of alpha-synuclein toxicity in dopaminergic neurodegeneration using a novel in vivo assay
Principal investigators: Kalia, Lorraine V
Keywords: Alpha-Synuclein; C. Elegans; Genetic Screen; Lewy Bodies; Molecular Signalling; Neurodegeneration; Parkinson'S Disease; Protein-Protein Interactions
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.